RSV: The Disease and Pipeline Vaccines
Despite effectiveness and safety issues, a vaccine targeting Respiratory Syncytial Virus (RSV) by GlaxoSmithKline Biologicals (GSK) was approved by the FDA on May 3, 2023 for people ages 60 and older, and now Pfizer’s RSV vaccine targeting pregnant women is moving through the perfunctory steps of captured federal agencies on it’s way to licensing. Listen to …